LONDON, Dec. 9, 2015 (GLOBE NEWSWIRE) -- LivaNova PLC (NASDAQ:LIVN) (LSE:LIVN) ("LivaNova" or the "Company") today announced the appointment of Berenberg as Corporate Broker to the Company with immediate effect.
LivaNova, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A. ("Sorin"), a leader in the treatment of cardiovascular diseases, and Cyberonics, a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The Company employs approximately 4,500 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.
LivaNova is listed on NASDAQ and has been admitted to the standard listing segment of the Official List of the UK's Financial Conduct Authority and to trading on the London Stock Exchange (LSE) under the ticker symbol "LIVN".
Safe harbor statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Forward-looking statements are based on management's current beliefs and assumptions, based on presently available information, and describe the Company's future plans, strategies and expectations. Investors are cautioned that all such statements involve risks and uncertainties that could cause actual results and outcomes to differ materially from those expected, including without limitation, statements concerning developing novel opportunities in heart failure, sleep apnea and percutaneous mitral valve, creating new innovative solutions that benefit patients, healthcare professionals, and healthcare systems, and building significant shareholder value. Further information regarding these risks and uncertainties can be found in LivaNova's public filings, including its Registration Statement on Form S-4, Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the United States Securities and Exchange Commission. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please visit www.livanova.com, or contact:
|Investor Relations:||Investor Relations and Media:|
|Vivid Sehgal||Greg Browne|
|Chief Financial Officer||Senior Vice President, Finance|
|Phone: +44 (0)203 786 5281||Phone: +1 (281) 228-7262|
|Fax: +44 (0)203 786 5291||Fax: +1 (281) 218-9332|
|e-mail: email@example.com||e-mail: firstname.lastname@example.org|